Gastrointestinal Stromal TumorLocally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancerAdvanced renal cell carcinoma (first-line, in combination with pembrolizumab)Advanced renal cell carcinoma following one prior anti-angiogenic therapy (in combination with everolimus)Unresectable hepatocellular carcinoma (first-line)Advanced endometrial carcinoma that is mismatch repair proficient (pMMR) or not microsatellite instability-high (MSI-H) following prior systemic therapy (in combination with pembrolizumab)Gastric CancerGastroesophageal Junction AdenocarcinomaNon-Small Cell Lung CancerColorectal CancerHepatocellular CarcinomaRenal Cell CarcinomaPancreatic Neuroendocrine TumorMetastatic RET fusion-positive non-small cell lung cancerAdvanced or metastatic RET fusion-positive thyroid cancerGastrointestinal stromal tumor (GIST)Advanced renal cell carcinoma (RCC)Adjuvant treatment of renal cell carcinoma (RCC) at high risk of recurrence following nephrectomyProgressive, well-differentiated pancreatic neuroendocrine tumors (pNET)Metastatic colorectal cancerLocally advanced, unresectable or metastatic gastrointestinal stromal tumorHepatocellular carcinomaIdiopathic Pulmonary FibrosisInterstitial Lung DiseaseSystemic Sclerosis-Associated Interstitial Lung Disease

All Drugs Targeting VEGFR2

Drug	Company	Approved	Indications	Therapeutic Area
LENVIMA	EISAI INC	2015	5
CYRAMZA	Eli Lilly	2014	5	Oncology
SUTENT	CPPI CV	2006	4
SUNITINIB MALATE	NATCO PHARMA	2021	3	Oncology
STIVARGA	Bayer	2012	3
OFEV	Boehringer Ingelheim	2014	3	Respiratory
GAVRETO	BLUEPRINT MEDICINES	2020	2
QINLOCK	DECIPHERA PHARMS	2020	1